Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319810 · ClinicalTrials.gov registry record · Phase 2
Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease
A Phase 2 study, sponsored by Sutter Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03319810 is a Phase 2 study that has completed, run by Sutter Health. The registered enrollment target is 5 participants.
The verdict
NCT03319810, a Phase 2 study, has completed, sponsored by Sutter Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a proof of concept study to determine if changes in brain amyloid levels are evident three months after infusion of 0.4 g/kg of IVIG every 14 days x 5 infusions. Amyloid levels will be measured by Florbetapir PET and retinal scan.
Interventions
- BIOLOGICAL Octagam 10%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-04 |
| Est. Completion | 2018-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03319810
The ClinicalTrials.gov registry entry for NCT03319810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutter Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Octagam 10% is the first listed.
NCT03319810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03319810 about?
NCT03319810 is a clinical study titled "Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease". This is a proof of concept study to determine if changes in brain amyloid levels are evident three months after infusion of 0.4 g/kg of IVIG every 14 days x 5 infusions. Amyloid levels will be measured by Florbetapir PET and retinal scan.
What is the current status of trial NCT03319810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-01-04. Estimated completion is 2018-07-19.
What interventions are being tested in trial NCT03319810?
The interventions under investigation include: Octagam 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT03319810?
This trial is sponsored by Sutter Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.